Literature DB >> 26399481

The activating role of phospho-(Tyr)-calmodulin on the epidermal growth factor receptor.

Silviya R Stateva1, Valentina Salas2, Alberto Benguría3, Itziar Cossío3, Estefanía Anguita1, José Martín-Nieto4, Gustavo Benaim5, Antonio Villalobo6.   

Abstract

The activity of calmodulin (CaM) is modulated not only by oscillations in the cytosolic concentration of free Ca(2+), but also by its phosphorylation status. In the present study, the role of tyrosine-phosphorylated CaM [P-(Tyr)-CaM] on the regulation of the epidermal growth factor receptor (EGFR) has been examined using in vitro assay systems. We show that phosphorylation of CaM by rat liver solubilized EGFR leads to a dramatic increase in the subsequent phosphorylation of poly-L-(Glu:Tyr) (PGT) by the receptor in the presence of ligand, both in the absence and in the presence of Ca(2+). This occurred in contrast with assays where P-(Tyr)-CaM accumulation was prevented by the presence of Ca(2+), absence of a basic cofactor required for CaM phosphorylation and/or absence of CaM itself. Moreover, an antibody against CaM, which inhibits its phosphorylation, prevented the extra ligand-dependent EGFR activation. Addition of purified P-(Tyr)-CaM, phosphorylated by recombinant c-Src (cellular sarcoma kinase) and free of non-phosphorylated CaM, obtained by affinity-chromatography using an immobilized anti-phospho-(Tyr)-antibody, also increased the ligand-dependent tyrosine kinase activity of the isolated EGFR toward PGT. Also a CaM(Y99D/Y138D) mutant mimicked the effect of P-(Tyr)-CaM on ligand-dependent EGFR activation. Finally, we demonstrate that P-(Tyr)-CaM binds to the same site ((645)R-R-R-H-I-V-R-K-R-T-L-R-R-L-L-Q(660)) as non-phosphorylated CaM, located at the cytosolic juxtamembrane region of the EGFR. These results show that P-(Tyr)-CaM is an activator of the EGFR and suggest that it could contribute to the CaM-mediated ligand-dependent activation of the receptor that we previously reported in living cells.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  calcium; calmodulin; epidermal growth factor receptor; phospho-(Tyr)-calmodulin; tyrosine kinase

Mesh:

Substances:

Year:  2015        PMID: 26399481     DOI: 10.1042/BJ20150851

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  7 in total

Review 1.  Calmodulin and PI3K Signaling in KRAS Cancers.

Authors:  Ruth Nussinov; Guanqiao Wang; Chung-Jung Tsai; Hyunbum Jang; Shaoyong Lu; Avik Banerjee; Jian Zhang; Vadim Gaponenko
Journal:  Trends Cancer       Date:  2017-02-18

2.  Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of tumor cells while they enhance attachment to the substrate.

Authors:  Juan Alcalde; María González-Muñoz; Antonio Villalobo
Journal:  Heliyon       Date:  2020-05-07

Review 3.  The multifunctional role of phospho-calmodulin in pathophysiological processes.

Authors:  Antonio Villalobo
Journal:  Biochem J       Date:  2018-12-21       Impact factor: 3.857

4.  CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma.

Authors:  Tao Liu; Xiujuan Han; Shutao Zheng; Qing Liu; Aerziguli Tuerxun; Qiqi Zhang; Lifei Yang; Xiaomei Lu
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

Review 5.  Calmodulin: The switch button of calcium signaling.

Authors:  Chiu-Fen Yang; Wen-Chin Tsai
Journal:  Tzu Chi Med J       Date:  2021-08-23

6.  Deciphering the Heterogeneity of the Internal Environment of Hippocampal Neurons during Maturation by Raman Spectroscopy.

Authors:  Xiaodong Kong; Haoyue Liang; Kexuan Zhou; Haoyu Wang; Dai Li; Shishuang Zhang; Ning Sun; Min Gong; Yuan Zhou; Qiang Zhang
Journal:  ACS Omega       Date:  2022-08-19

7.  Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma.

Authors:  Xu Hannah Zhang; Jack Hsiang; Steven T Rosen
Journal:  J Clin Haematol       Date:  2021-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.